American Century Companies Inc. Takes $4.68 Million Position in Cellebrite DI Ltd. $CLBT

Key Points

• American Century Companies Inc. purchased 240,795 shares of Cellebrite DI Ltd. worth approximately $4.68 million, constituting about 0.10% of the company's stock.
• Cellebrite DI reported a positive earnings per share (EPS) of $0.12 for the last quarter, surpassing analysts' estimates and showing an 18.4% increase in revenue year-over-year.
• Analyst ratings for the stock have seen adjustments, with Needham & Company lowering their price target to $18.00, while multiple firms continue to maintain a "buy" rating.

American Century Companies Inc. acquired a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 240,795 shares of the company's stock, valued at approximately $4,679,000. American Century Companies Inc. owned 0.10% of Cellebrite DI at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the business. HighTower Advisors LLC boosted its position in shares of Cellebrite DI by 16.3% in the first quarter. HighTower Advisors LLC now owns 14,485 shares of the company's stock valued at $281,000 after acquiring an additional 2,029 shares during the period. Nuveen LLC acquired a new position in shares of Cellebrite DI in the first quarter valued at approximately $15,031,000. Entropy Technologies LP acquired a new position in shares of Cellebrite DI in the first quarter valued at approximately $660,000. Polen Capital Management LLC increased its stake in shares of Cellebrite DI by 47.1% in the first quarter. Polen Capital Management LLC now owns 14,849 shares of the company's stock valued at $289,000 after buying an additional 4,754 shares during the period. Finally, Invesco Ltd. increased its position in Cellebrite DI by 122.1% during the 1st quarter. Invesco Ltd. now owns 3,296,079 shares of the company's stock valued at $64,043,000 after purchasing an additional 1,811,757 shares during the period. Institutional investors own 45.88% of the company's stock.

Cellebrite DI Stock Performance

NASDAQ:CLBT traded down $0.14 during mid-day trading on Thursday, reaching $16.37. The stock had a trading volume of 4,336,036 shares, compared to its average volume of 2,422,649. The firm has a 50 day moving average price of $15.01 and a two-hundred day moving average price of $17.06. The stock has a market capitalization of $3.92 billion, a P/E ratio of -21.54, a P/E/G ratio of 3.00 and a beta of 1.28. Cellebrite DI Ltd. has a one year low of $13.10 and a one year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The firm had revenue of $113.28 million during the quarter, compared to the consensus estimate of $112.33 million. During the same quarter in the previous year, the company posted $0.10 earnings per share. The business's revenue was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analyst Upgrades and Downgrades

CLBT has been the subject of a number of recent analyst reports. Wall Street Zen raised shares of Cellebrite DI from a "hold" rating to a "buy" rating in a research report on Saturday, August 16th. JPMorgan Chase & Co. cut their target price on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a report on Monday, May 12th. Lake Street Capital dropped their price objective on Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a research note on Friday, August 15th. Finally, Needham & Company LLC decreased their target price on Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a research report on Thursday, August 14th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $22.40.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.